DOWNLOAD THIS REPORT HERE (PDF) Free Cash Flow (“FCF”) Yield is one of the most important fundamental metrics indicating a...
Read More
The breaking news this week in gene editing was Pfizer Inc. will pay as much as $1.35 billion to partner with Beam Therapeutics Inc. on developing drugs for rare genetic diseases using base editing, a technology for manipulating DNA.
From Barron’s:
Gene editing is the next phase of genetic medicine, and another big step was just announced. Monday morning, Pfizer unveiled a $1.3 billion partnership with Beam Therapeutics to develop three treatments for genetic disease in the next four years. They’ll use Beam’s leading-edge technology that makes precise corrections to typographical errors in our genes—a technology called “base editing”.
Beam is a top constituent in the XDNA Index
[NAME] SITE
Thank you for visiting Kelly Intelligence
You are now being redirected to our [NAME] site.